A Drug Called AVM0703 for People With Solid Tumors or Blood Cancers
Original title: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, so this is still a study drug and not regular care.
Status: Available. It is open outside of a trial for people who qualify.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study looks at a drug called AVM0703 in people with solid tumors or blood cancers.
Who this trial is for. This is for people with solid tumors or blood cancers. A US doctor must ask for the drug on the person's behalf. The drug, AVM0703, acts on the immune system.
Where it stands. The source does not report results. As of July 2024, 37 patients had been treated. Side effects from the drug were mostly mild. They include itching during the infusion and about 1 week of mild trouble sleeping.
What this means, and what it doesn't
What it could mean: Someone with one of these cancers could ask their care team about this. The care team can say if it makes sense to look into.
What it doesn't mean: This does not mean the drug is proven to work. A study drug is still being tested. Getting it is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.